WSJ
22 Oct 2026, 08:23 UTC · 2h ago
Impact · against what's priced in
UCB is likely to see a sustained upward revision in EPS estimates following a second guidance raise this year. Stronger-than-expected U.S. demand for Bimzelx provides a concrete catalyst for growth that exceeds previous annual projections.
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
UCB raised its annual guidance for the second time this year due to strong U.S. demand for Bimzelx.
NewShares jumped 13% following the guidance raise
So whatThis second upward revision suggests a sustained trend that will likely force analysts to raise full-year EPS estimates.
More positive than 99% of claims this week
Continue reading
5 related stories
Read next
GlobeNewsWire · 5h ago
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
1h ago
